2017

Exco InTouch receives privacy shield framework self-certification

Tuesday, January 17, 2017

ERT company Exco InTouch, a provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, has formally received EU-U.S. Privacy Shield Framework Self-Certification status by the U.S. Department of Commerce’s International Trade Administration (ITA). The designation certifies that Exco InTouch’s practices meet or exceed the data privacy and security principles outlined by U.S. Department of Commerce and European Commission.

[Read More]

Malecare launches trial accrual system Cancergraph

Tuesday, January 17, 2017

Malecare, a U.S. men’s cancer survivor support and advocacy national nonprofit organization, launched Cancergraph, a mobile application that tracks cancer symptoms, disease states and quality of life reports in real time and quickly identified its primary value as a clinical trial accrual system. Cancergraph distills each users’ health data to provide, in real time, only the specific cancer trials that apply to them. 

[Read More]

Chi-Med appoints Paul Carter to board of directors

Monday, January 16, 2017

Hutchison China MediTech (Chi-Med) has announced, effective from February 1, Paul Rutherford Carter has been appointed as senior independent non-executive director and member of the audit committee, Remuneration Committee and Technical Committee of Chi-Med; and Shigeru Endo tendered his resignation as non-executive director and Christopher Nash tendered his resignation as senior independent non-executive director and member of audit committee and remuneration committee effective on the same date.

[Read More]

Nivalis Therapeutics restructures

Monday, January 16, 2017

Nivalis Therapeutics, a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), has announced that its board of directors has approved a restructuring plan as part of the company’s initiative to explore strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.

[Read More]

Merck KGaA, Palantir partnership on healthcare acceleration

Monday, January 16, 2017

Merck KGaA, a science and technology company, has announced a partnership with Palantir Technologies, developer of data integration and analysis software, at Palantir’s headquarters in Palo Alto, California. The partnership will leverage Palantir’s advanced data analytics capabilities to help Merck better and more rapidly develop and deliver medicines to patients, commercialize new products and improve patient outcomes. Initially, Merck will apply Palantir’s technology to cancer treatment and patient services. Ultimately Merck plans to deploy Palantir’s technology across all three of the company’s business sectors Healthcare, Life Science and Performance Materials. Financial details were not disclosed.

[Read More]

Report: Biopharmaceutical M&A expected to soar in 2017

Monday, January 16, 2017

The biopharmaceutical industry’s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M&A) environment in 2017. This is according to the EY M&A Outlook and Firepower Report 2017. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election U.S., expectations are that the industry may roar past the $200 billion in global M&A deal volume seen in the last three years.

[Read More]